Clinical Trial Update: OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy) [Phase 2]

View source ↗

Summary

A Phase 2 trial of dasatinib as optimized monotherapy for BCR-ABL positive chronic myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: Versailles Hospital | Conditions: Chronic Myelogenous Leukemia, BCR/ABL Positive | Phase 2 | Status: COMPLETED